Table 1.
Comparisons of monocyte abundances in BM and PB between the remission (n = 44) and relapse (n = 45) cohorts
| % Myeloid compartment (median IQR) | Remission (n = 44) | Relapse (n = 45) | P value (univariate) | P value (multivariate) |
|---|---|---|---|---|
| PB | ||||
| CD14+CD16– | 31.18 (14.92-49.11) | 23.41 (11.59-48.85) | 0.148 | .113 |
| CD14+CD16+ | 9.02 (5.23-17.67) | 10.68 (4.97-13.81) | 0.715 | .240 |
| CD14–CD16+ | 54.40 (24.26-68.14) | 60.94 (36.49-80.27) | 0.0887 | .038 |
| BM | ||||
| CD14+CD16– | 49.88 (23.30-72.27) | 41.63 (23.89-66.30) | 0.667 | .374 |
| CD14+CD16+ | 7.84 (3.81-12.12) | 8.31 (2.86-16.67) | 0.905 | .600 |
| CD14–CD16+ | 39.55 (17.32-65.18) | 44.32 (17.61-61.13) | 0.685 | .544 |
Univariate analysis: The nonparametric Wilcoxon rank sum test (2-tailed) was used to compare the monocyte abundances between remission and relapse.
Multivariate analysis: logistic regression of the response outcome (relapse vs remission) on monocyte abundances (2-tailed Wald test) was used to assess the association between monocyte abundances and response with adjustment of potential confounding factors including age, sex, CNS status, NCI risk, genetic subtype, and WBC level at diagnosis, and EOI MRD.
IQR, interquartile range. Bold indicates P value < 0.05.